Tuesday , 12 November 2019
Home / Education / Nigerian Doctor wins “Brain Tumor Research” award in U.S. 

Nigerian Doctor wins “Brain Tumor Research” award in U.S. 

 Dr Chibawanye Ene, a US-based Nigerian Doctor, has won the 2019 Ronald L. Bittner Award on Brain Tumor Research. A statement from the Clinical Department, Applied Radiation Oncology U.S., said Ene received the award at the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting held from April 13 to April 17 in San Diego.
The-37-year-old, who is from Akpugo in Nkanu West Local Government Area of Enugu State, won the award with his research work on ‘Anti-PD-L1 Immunotherapy Enhances Radiation-induced Abscopal Response in Glioblastoma’. Journalists gathered that Immunotherapy is a type of cancer treatment that helps the immune system fight cancer. EFCC to Saraki: Don’t be afraid if you have nothing to hide, we are doing our job The immune system made up of white blood cells, organs and tissues of the lymph system help the body fight infections and other diseases. The Clinical Department stated Immunotherapy is a type of biological therapy. Also, Glioblastoma, known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke.
Immunotherapy for glioblastoma has been largely unsuccessful in part because molecular heterogeneity drives selective elimination of only a subset of tumour cells. According to the statement, it appears that therapeutic success in patients would require achieving an abscopal effect, where following focused radiation therapy, non-targeted tumour cells are attacked by the immune system
AmarSim Associations Development Consultants

Check Also

Northern Govs frustrating basic education for Almajiris – Ex UBEC Boss

By AbdulGafar Alabelewe, Kaduna Governors of 19 Northern States are responsible for frustrating the integration …

Leave a Reply

Your email address will not be published. Required fields are marked *